MRD Tracking May Allow More ‘Individualized’ Management of Multiple Myeloma

Video

C. Ola Landgren, MD, PhD, illustrated how minimal residual disease tracking may allow greater treatment personalization in the future.

In an interview with CancerNetwork®, C. Ola Landgren, MD, PhD, touched on one of the most important issues that went undiscussed during a recent Around the Practice® program: the future of minimal residual disease (MRD) tracking in multiple myeloma.

Landgren is a professor of hematology, chief of the Myeloma Section, leader of the Experimental Therapeutics Program, and co-leader of the Tumor Biology Program at the University of Miami Sylvester Comprehensive Cancer Program. He spoke about how treatment intensity could be determined by MRD status in the future, which may yield improvements in efficacy.

He also remarked on other potential developments in MRD tracking, including the development of blood-based tests. Through this, he predicted an increase in individualized disease management in the future.

Transcript:

We covered many of the important trends in the field today, [but] one thing we didn’t talk much about is the utility of MRD tracking. As these technologies become [more] available, even [in the form of] blood-based tests, they will help the field [move] forward. We will [likely] see more individualized [disease] management; patients will have the intensity of their therapy increased or decreased based on MRD status. [For example], for a patient who is MRD-negative after a certain number of cycles, you could [consider] decreasing [therapy] and [switching] to maintenance. Conversely, if there is evidence of rising markers, the patient would convert back to MRD positivity, [which] in the future may trigger [the use of] some newer therapies. Basically, it will be a molecular relapse. That’s how I envision the field going forward.

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
4 experts in this video
Related Content